# A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

> **NCT07559175** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Aimmune Nestlé Health Science US R&D, LLC** · enrollment: 66 (estimated)

## Conditions studied

- Exocrine Pancreatic Insufficiency (EPI)
- Cystic Fibrosis (CF)
- Pancreatic Enzyme Abnormality
- Pancreatic Diseases

## Interventions

- **DRUG:** NHS7108
- **DRUG:** Zenpep®

## Key facts

- **NCT ID:** NCT07559175
- **Lead sponsor:** Aimmune Nestlé Health Science US R&D, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-06
- **Final completion:** 2027-09
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07559175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07559175, "A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07559175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*